SRPT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Sarepta Therapeutics Inc (SRPT) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown promising early-stage clinical data for its siRNA programs, the financial performance is significantly weak, with declining revenue, net income, and gross margin. Additionally, hedge funds are selling the stock, and there is no strong signal from proprietary trading indicators to suggest immediate action. The stock may be worth monitoring for further developments, but it is not an optimal entry point right now.
The MACD is positively expanding, suggesting bullish momentum, while RSI is neutral at 69.384. Moving averages are converging, indicating no clear trend. The stock is trading near its resistance level (R1: 22.308), which may act as a barrier to further upward movement.
Promising Phase 1/2 clinical data for SRP-1001 and SRP-1003 with strong muscle drug concentrations and a good safety profile. Analysts have raised price targets, and the siRNA platform shows potential for long-term value creation.
Hedge funds are selling heavily, with a 12693.27% increase in selling activity. Financial performance is deteriorating significantly, with a YoY revenue drop of -32.73% and net income down -277.84%. Analysts are cautious about the early-stage nature of the clinical data, and some believe the recent stock rally is overdone.
In 2025/Q4, revenue dropped to $442.93M (-32.73% YoY), net income fell to -$282.85M (-277.84% YoY), and EPS declined to -$2.7 (-304.55% YoY). Gross margin also decreased to 47.15% (-40.92% YoY), indicating significant financial challenges.
Mixed analyst sentiment. Outperform ratings from Wedbush, Oppenheimer, and Mizuho with price targets ranging from $29 to $37. However, Deutsche Bank and Citi maintain Sell ratings, citing concerns about the early-stage data and overreaction to the recent rally.
